FDA Puts Clinical Hold On Telcyta Following ASCO Presentation
This article was originally published in The Pink Sheet Daily
Executive Summary
Telik plans to submit additional safety and other information to FDA and request a meeting with the agency “as soon as possible.”
You may also be interested in...
Troubled Biotechs: Orexigen, Telik, Trubion
Vanda’s recent good news gives U.S. biotechs hope for a turnaround, while BIO’s Greenwood predicts most will survive the credit crunch.
Troubled Biotechs: Orexigen, Telik, Trubion
Vanda’s recent good news gives U.S. biotechs hope for a turnaround, while BIO’s Greenwood predicts most will survive the credit crunch.
Telik Will Continue Developing Telcyta Despite Three Phase III Failures
Firm says an independent review shows its ASSIST-3 trial may have been compromised by inappropriately dropped patients.